article thumbnail

Key Trends in the Life Sciences to Look Forward to in 2022

XTalks

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. RNA technology is not new nor has its potential been surprising. RNA in the Making. So why did this perceived RNA ‘revolution’ take so long?

article thumbnail

Amvuttra RNAi Therapeutic Wins FDA Approval for Rare Genetic Protein Disorder

XTalks

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics

Delveinsight

Terns schedules to bring a third candidate into the clinic this year, TERN-501, a thyroid hormone receptor (THR) beta-agonist. Ribometrix will apply its proprietary discovery platform to recognize and optimize small molecule compounds, which modulate RNA function by aiming three-dimensional (3D) RNA structures.

RNA 52
article thumbnail

Alnylam finds belly fat gene and drug target in UK Biobank study

pharmaphorum

The RNA interference specialist says its researchers and collaborators have identified mutations in a gene called INHBE that are associated with protection against abdominal obesity and metabolic syndrome – a condition impacting more than 20% of adults worldwide.

article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause. It was the third approval from Alnylam’s pipeline of RNA interference therapeutics to make it to market.

article thumbnail

Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19

Pfizer

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Contraception : Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Drugs 99
article thumbnail

From Gene to Protein: The Journey of Protein Expression Technology

Roots Analysis

Protein expression is a potent technology in the field of synthetic biology, that is utilized for the high-throughput production of proteins as well as enzymes and oligonucleotides (DNA / RNA). This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40